{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T07:00:09Z","timestamp":1761807609102},"reference-count":22,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2010,12,23]],"date-time":"2010-12-23T00:00:00Z","timestamp":1293062400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Respirology"],"published-print":{"date-parts":[[2011,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p><jats:bold>Background and objective:\u2003<\/jats:bold> Dry powder mannitol has the potential to be used to enhance clearance of mucus in subjects with bronchiectasis. A reduction in FEV<jats:sub>1<\/jats:sub> has been recorded in some subjects with bronchiectasis after inhaling mannitol. The aim of this study was to investigate if pre\u2010medicating with either sodium cromoglycate (SCG) or eformoterol could inhibit this reduction in FEV<jats:sub>1<\/jats:sub>.<\/jats:p><jats:p><jats:bold>Methods:\u2003<\/jats:bold> A double\u2010blind, placebo\u2010controlled, randomized cross\u2010over study was conducted. Lung function and airway response to mannitol was assessed on a control day and then re\u2010assessed after pre\u2010medication with placebo, SCG and eformoterol in nine subjects. Sensitivity to mannitol, expressed as the dose required to induce a 15% fall in FEV<jats:sub>1<\/jats:sub> (PD<jats:sub>15<\/jats:sub>), and reactivity to mannitol, expressed as the % fall in FEV<jats:sub>1<\/jats:sub> per mg of mannitol (response\u2013dose ratio, RDR), are reported.<\/jats:p><jats:p><jats:bold>Results:\u2003<\/jats:bold> Subjects had an FEV<jats:sub>1<\/jats:sub> of 68\u2003\u00b1\u200314% predicted, FVC of 97\u2003\u00b1\u200315% predicted and FEV<jats:sub>1<\/jats:sub>\/FVC of 71\u2003\u00b1\u20038%. They were mildly hypoxemic and the SpO<jats:sub>2<\/jats:sub> was 95\u2003\u00b1\u20032%.They had a PD<jats:sub>15<\/jats:sub> to mannitol of 235\u2003mg (95% CI: 150\u2013368\u2003mg) and a RDR of 0.057% fall in FEV<jats:sub>1<\/jats:sub> per mg (95% CI: 0.038\u20130.085). After pre\u2010medication with SCG, PD<jats:sub>15<\/jats:sub> increased (773\u2003mg, <jats:italic>P<\/jats:italic>\u2003&lt;\u20030.05) and RDR was reduced (0.013, <jats:italic>P<\/jats:italic>\u2003&lt;\u20030.05). Pre\u2010medication with eformoterol also resulted in an increased PD<jats:sub>15<\/jats:sub> (1141\u2003mg, <jats:italic>P<\/jats:italic>\u2003&lt;\u20030.01) and a reduced RDR (0.009, <jats:italic>P<\/jats:italic>\u2003&lt;\u20030.01). A small but significant decrease in SpO<jats:sub>2<\/jats:sub> from baseline was noted after mannitol in the presence of SCG (<jats:italic>P<\/jats:italic>\u2003&lt;\u20030.05).<\/jats:p><jats:p><jats:bold>Conclusions:\u2003<\/jats:bold> Pre\u2010medication with either SCG or eformoterol protects patients with bronchiectasis from developing a significant reduction in FEV<jats:sub>1<\/jats:sub> after inhaling mannitol.<\/jats:p>","DOI":"10.1111\/j.1440-1843.2010.01894.x","type":"journal-article","created":{"date-parts":[[2010,11,7]],"date-time":"2010-11-07T09:54:42Z","timestamp":1289123682000},"page":"161-166","source":"Crossref","is-referenced-by-count":11,"title":["Sodium cromoglycate and eformoterol attenuate sensitivity and reactivity to inhaled mannitol in subjects with bronchiectasis"],"prefix":"10.1111","volume":"16","author":[{"given":"Peter J.","family":"BRIFFA","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra D.","family":"ANDERSON","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah L.","family":"BURTON","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iven H.","family":"YOUNG","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2010,12,23]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.159.6.9809074"},{"key":"e_1_2_6_3_2","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3810\/pgm.1999.07.607","article-title":"Bronchiectasis: the \u2018other\u2019 obstructive lung disease","volume":"106","author":"Mysliwiec V","year":"1999","journal-title":"Postgrad. Med."},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccm.2007.02.014"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1385\/CRIAI:25:3:233"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.97.10112449"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.119.2.414"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1843.2005.00659.x"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.156.3.9701113"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.158.4.9802087"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.124.6.2171"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1186\/1465-9921-6-144"},{"issue":"51","key":"e_1_2_6_13_2","first-page":"306s","article-title":"Prevalence of bronchoconstriction in patients with bronchiectasis assessed prior to treatment with a dry powder preparation of mannitol","volume":"30","author":"Anderson SD","year":"2007","journal-title":"Eur. Respir. J."},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.06.00078205"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1183\/09041950.005s1693"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.124.4.1341"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1099-0496(199605)21:5<282::AID-PPUL3>3.0.CO;2-P"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm\/143.3_Pt_2.S52"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.03.00113403"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.164.2.2101105"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.2165\/00151829-200403060-00004"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1385\/CRIAI:31:2:163"},{"key":"e_1_2_6_23_2","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1183\/09031936.94.07111973","article-title":"Bronchoprotection by salmeterol: cell stabilization or functional antagonism? Comparative effects on histamine\u2010 and AMP\u2010induced bronchoconstriction","volume":"7","author":"Sol\u00e8r M","year":"1994","journal-title":"Eur. Respir. J."}],"container-title":["Respirology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1440-1843.2010.01894.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1440-1843.2010.01894.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T01:40:06Z","timestamp":1697247606000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1440-1843.2010.01894.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,12,23]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,1]]}},"alternative-id":["10.1111\/j.1440-1843.2010.01894.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1440-1843.2010.01894.x","archive":["Portico"],"relation":{},"ISSN":["1323-7799","1440-1843"],"issn-type":[{"value":"1323-7799","type":"print"},{"value":"1440-1843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,12,23]]}}}